190 related articles for article (PubMed ID: 30704537)
21. Association of PET-based stages of amyloid deposition with neuropathological markers of Aβ pathology.
Teipel SJ; Temp AGM; Levin F; Dyrba M; Grothe MJ;
Ann Clin Transl Neurol; 2021 Jan; 8(1):29-42. PubMed ID: 33137247
[TBL] [Abstract][Full Text] [Related]
22. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
24. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
25. Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation.
Arenaza-Urquijo EM; Bejanin A; Gonneaud J; Wirth M; La Joie R; Mutlu J; Gaubert M; Landeau B; de la Sayette V; Eustache F; Chételat G
Neurobiol Aging; 2017 Nov; 59():72-79. PubMed ID: 28764930
[TBL] [Abstract][Full Text] [Related]
26. Associations Between Cognitive Complaints, Memory Performance, Mood, and Amyloid-β Accumulation in Healthy Amyloid Negative Late-Midlife Individuals.
Narbutas J; Van Egroo M; Chylinski D; Bahri MA; Koshmanova E; Talwar P; Besson G; Muto V; Schmidt C; Luxen A; Balteau E; Phillips C; Maquet P; Salmon E; Bastin C; Vandewalle G; Collette F
J Alzheimers Dis; 2021; 83(1):127-141. PubMed ID: 34275899
[TBL] [Abstract][Full Text] [Related]
27. Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.
Teipel SJ; Dyrba M; Vergallo A; Lista S; Habert MO; Potier MC; Lamari F; Dubois B; Hampel H; Grothe MJ
Front Aging Neurosci; 2021; 13():748198. PubMed ID: 35002673
[No Abstract] [Full Text] [Related]
28. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
29. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
[TBL] [Abstract][Full Text] [Related]
30. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
[TBL] [Abstract][Full Text] [Related]
31. Repetitive negative thinking is associated with amyloid, tau, and cognitive decline.
Marchant NL; Lovland LR; Jones R; Pichet Binette A; Gonneaud J; Arenaza-Urquijo EM; Chételat G; Villeneuve S;
Alzheimers Dement; 2020 Jul; 16(7):1054-1064. PubMed ID: 32508019
[TBL] [Abstract][Full Text] [Related]
32. Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease.
Cacciamani F; Tandetnik C; Gagliardi G; Bertin H; Habert MO; Hampel H; Boukadida L; Révillon M; Epelbaum S; Dubois B;
J Alzheimers Dis; 2017; 59(2):753-762. PubMed ID: 28671134
[TBL] [Abstract][Full Text] [Related]
33. PET staging of amyloidosis using striatum.
Hanseeuw BJ; Betensky RA; Mormino EC; Schultz AP; Sepulcre J; Becker JA; Jacobs HIL; Buckley RF; LaPoint MR; Vannini P; Donovan NJ; Chhatwal JP; Marshall GA; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; ;
Alzheimers Dement; 2018 Oct; 14(10):1281-1292. PubMed ID: 29792874
[TBL] [Abstract][Full Text] [Related]
34. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
35. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.
Timmers T; Ossenkoppele R; Verfaillie SCJ; van der Weijden CWJ; Slot RER; Wesselman LMP; Windhorst AD; Wolters EE; Yaqub M; Prins ND; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BNM
Neurobiol Aging; 2019 Jul; 79():50-58. PubMed ID: 31026622
[TBL] [Abstract][Full Text] [Related]
36. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
37. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
[TBL] [Abstract][Full Text] [Related]
38. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
[TBL] [Abstract][Full Text] [Related]
39. Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition.
Tolbert S; Liu Y; Hellegers C; Petrella JR; Weiner MW; Wong TZ; Murali Doraiswamy P
J Prev Alzheimers Dis; 2019; 6(4):274-282. PubMed ID: 31686100
[TBL] [Abstract][Full Text] [Related]
40. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.
Marshall GA; Gatchel JR; Donovan NJ; Muniz MC; Schultz AP; Becker JA; Chhatwal JP; Hanseeuw BJ; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
J Alzheimers Dis; 2019; 67(2):757-768. PubMed ID: 30689584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
